Close Menu

NEW YORK – Immuno-oncology imaging firm ImaginAb has initiated a Phase II trial of its positron emission tomography (PET) imaging agent [89] Zr-Df-IAB22M2C at Dana-Farber Cancer Institute.

The imaging agent uses antibody fragments, so called "minibodies," engineered by ImaginAb to target CD8-positive T cells, and illuminate them with the help of PET imaging. The platform is being developed to provide a whole-body snapshot of immune activity, including that of cancer lesions, which in turn could be used to tailor treatment more precisely to patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Genomics is a key element in the potential of precision medicine to transform oncology. 


This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Sponsored by

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.